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ABSTRACT 
Many inhalation exposure studies have been performed with toluene diisocyanate (TDI) in 
different animal species. Many were targeted at respiratory irritation and/or sensitisation. As 
there is still no broadly accepted guideline for the performance of respiratory sensitisation 
tests, protocols used and endpoints investigated are numerous. In this review we collected da-
ta from those respiratory sensitisation and/or irritation studies that provided threshold or dose-
response information. Against this aim, and as TDI is a model substance for a respiratory sen-
sitiser, a great number of mechanistic studies are not cited in this paper, although they were 
checked for relevant information. The literature data available allow the conclusion that both 
respiratory irritation and sensitisation may be interdependent, and both irritation and sensitisa-
tion by TDI is a threshold phenomenon. Across species, the majority of NOAECs for respira-
tory sensitisation are in the range of 0.005 to 0.03 ppm, whereas the LOAEC is about 0.02 to 
0.4 ppm.  
 
Keywords: Toluene diisocyanate, respiratory sensitisation, animal models, asthma 
 
 
 
INTRODUCTION 
New onset asthma caused at the work-
place (Occupational asthma, OA) has be-
come a significant global concern. In the 
EU respiratory sensitizers are controlled by 
legislation and specifically included for 
warning by the hazard statement ”H334 
May cause allergy or asthma symptoms or 
breathing difficulties if inhaled” according 
to regulation 1272/2008/EC, and by risk 
phrase “R42 May cause sensitisation by in-
halation” according to directive 67/548/EC. 
Although many predictive models have 
been evaluated, there is as yet no interna-
tionally recognized animal method for iden-
tification of respiratory sensitisation. In 
practice the majority of respiratory sensitis-
ers have been identified through occupa-
tional studies and worker experience. For 
example, in the case of diisocyanates, tolu-
ene diisocyanate (TDI) was first reported as 
an asthmagen by Fuchs and Valade (1951). 
Now there is widespread experience and 
recognition that diisocyanates, as a chemi-
cal class, can be respiratory sensitisers in 
man.  
There is an increasing understanding 
that respiratory sensitisation must be a 
threshold phenomenon, that is to say there 
is a no-effect level for both the induction 
and elicitation stages (Arts et al., 2006). 
The factors affecting the thresholds are 
multiple (Kimber, 1996), and include the 
potency of the chemical itself, the route of 
exposure, the extent, duration and frequen-
cy of exposure as well as other factors in-
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cluding genetic susceptibility and other un-
derlying disease conditions.  
The purpose of this review is to exam-
ine the existing dataset for the diisocyanate 
TDI, to identify where the data show a 
threshold or dose-response for either induc-
tion or elicitation of respiratory hypersensi-
tivity.  
It should be noted that commercially 
used TDI is mostly an isomer mixture of 
80:20 2,4-TDI:2,6-TDI. In the following 
text, “TDI” can mean both, the pure 2,4-
isomer or the 80:20 mixture. In commercial 
use, the 65:35 isomer mixture as well as the 
pure 2,4-TDI are used in much lower 
amounts. As can be deduced from some of 
the publications cited, both isomers seem to 
be equipotent in terms of irritation and sen-
sitisation. 
 
MATERIALS AND METHODS 
We searched TOXLINE with phrases 
“(Toluene diisocyanate OR TDI) AND 
(respiratory OR lung) AND (guinea pig OR 
mouse OR rat OR rabbit OR hamster)” up 
to and including June 2012. It is not the 
purpose of this paper to enter into the dis-
cussion of the most appropriate animal 
model. Here, experiences with TDI in dif-
ferent animal models with the focus on 
dose-response and/or threshold are summa-
rized. The emphasis is on in-vivo studies, 
where at a minimum the challenge step was 
performed by inhalation. Other studies are 
cited only if they provide valuable input to 
the dose-response and threshold discussion. 
The data will be assessed for possible ap-
plication to human risk assessment.  
Some publications provided data that 
would allow calculation of a benchmark 
dose, but did not mention NOAECs or 
LOAECs. In these cases, we analyzed the 
data by applying the Benchmark Dose 
Software version 2.2 (US EPA, 2011). For 
the goodness of fit, we chose a value P ≥ 
0.1. In the computation, the program was 
set to generate the 10 % effect level above 
background (BMD10) and its lower 95 % 
confidence limit (BMDL10). When more 
than one dose-response model generated an 
acceptable fit to the experimental data, but 
BMD values differed by more than a factor 
of 3, model output with low Akaike’s In-
formation Criterium (AIC) was preferred 
(US EPA, 2011).  
 
Technical aspects of sensitisation proto-
cols 
 
Protein conjugates 
Sensitising agents are classified as be-
ing either low or high molecular weight. In 
fact the distinction is more realistically be-
tween very high and lower molecular 
weight, in that the high molecular weight 
sensitisers include animal protein, flour, 
wood dust, pollen etc. Low molecular 
weight allergens are usually chemicals with 
molecular weights below the 1500 kDa lev-
el. For TDI it is assumed that protein forms 
modified endogenously by binding of TDI 
molecules are involved in the response, and 
not TDI alone. It has often been found that 
obtaining a response to the parent molecule 
(TDI) may be difficult, whereas using a 
modified TDI-albumin protein will be ef-
fective. In several reports of animal models 
the abbreviation TDI-GSA or TDI-conju-
gate may be used, where GSA stands for 
guinea-pig serum albumin (or other letter-
species abbreviations as appropriate).  
Further, for small molecules that show 
some water solubility and/or tissue reactivi-
ty, it is likely that the target tissue – bron-
chiole – is not readily reached in the obli-
gate nose-breathing rodents. Aerosols of 
protein-conjugates are much less likely 
scrubbed out in the nose. 
Some investigators maintain that the use 
of conjugates for challenge is inappropriate 
as it represents an artificial challenge pro-
cess that cannot happen normally and so 
circumvents natural in vivo processes.  
 
Dose routes and exposure regimens 
It has long been suggested that induc-
tion by dermal contact is effective for res-
piratory sensitisation including TDI using 
laboratory animals (Karol et al., 1981; Rat-
tray et al., 1994). This allows the researcher 
to avoid technically difficult and costly in-
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halation exposures. It is fundamental that 
the challenge procedure should be a respira-
tory one. This may be relatively easy for 
volatile substances, but for non-volatile liq-
uids, solids and high molecular weight al-
lergens, this can be remarkably difficult. 
The intratracheal route has been used re-
cently in mouse respiratory sensitisation 
studies which eliminates the need for res-
piratory exposures (Driscoll et al., 2000). 
However, the technique has the disad-
vantage of delivering a large bolus of test 
material at one time and usually within a 
solvent. This potentially overloads any lo-
cal systems in the upper lung. While this 
may be useful for hazard identification pur-
poses, this technique is so out of step with 
occupational exposure that its use in risk 
assessment to humans must be questiona-
ble, at least in terms of dose-response and 
thresholds.  
 
Numbers of responders 
It is clear that even within the genetical-
ly homogenous test animal groups, individ-
uals may react differently to a stimulus. 
This is apparent even in hazard evaluation 
of skin and respiratory sensitisation, where 
results depend on number of responders in a 
group as well as the intensity of a response. 
Consequently some data include the num-
ber of responders and give displays of the 
individual response levels in the groups. 
With such datasets group means and stand-
ard errors are less helpful than numbers re-
sponding in a group.  
 
Irritation 
In sensitisation studies of skin, distin-
guishing between signs of irritation and 
signs of sensitisation have remained prob-
lematical. Both can result in similar lesions. 
Even the local lymph node assay (LLN), 
which is an assessment of induction meas-
uring cell division in a lymph node, has dif-
ficulty discriminating between irritation and 
sensitisation (McGarry, 2007). The newer 
techniques of cytokine profiling and gene 
regulation arrays demonstrate better ability 
to discriminate, although this is by no 
means settled. Indeed, many chemicals may 
have both irritant and sensitising activity, 
including TDI. A respiratory irritant may 
cause cough and rhinitis and these signs 
may also be encountered in the sensitisation 
response. In addition respiratory irritants 
reduce breathing rates in rodents, effective-
ly lowering the dose.  
For this report, a sensitisation protocol 
is one in which there is a challenge to the 
lung with TDI. The exception is the LLN 
assay which is an induction only protocol. 
Studies in which the responsiveness of the 
lung to other stimuli – that is pharmacolog-
ical or irritation – are taken as irritation 
studies.    
 
Animal models – induction and elicitation 
The various animal models for as-
sessing respiratory sensitisation have been 
reviewed by several authors (Kimber et al., 
1996; Pauluhn and Mohr, 2005; Johnson 
and Luster, 2006; Arts and Kuper, 2007; 
Pauluhn, 1996; Hoymann and Krug, 2001; 
Regal, 2004; Boverhoff et al., 2008.). 
Without reproducing the detailed accounts 
of these reviews, it can be noted that some 
tests assess either IgE or cytokine respons-
es, that is to say induction. In this context 
the use of the mouse LLN assay for skin 
sensitisation is an induction test which has 
been positive when tested against most low 
molecular weight respiratory sensitisers. In 
the induction phase, the skin is repeatedly 
exposed against slightly or clearly irritating 
doses of the agent. Some researchers inves-
tigated the non-specific hyperreactivity of 
the respiratory tract immediately after the 
induction phase. In tests for non-specific 
hyperresponsiveness, agonists of broncho-
constriction like acetylcholine (ACh) or 
methacholine (MCh) or other, irritating 
substances are applied below their irritation 
threshold and the physiological response 
(bronchoconstriction, change in breathing 
patterns) is monitored. This non-specific 
challenge may also be tested after a recov-
ery period - typically about 2 weeks - to 
avoid carry over from primary irritation. 
Non-specific airway hyperresponsiveness 
(AHR) is one of the hallmarks of occupa-
tional asthma. 
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Tests of elicitation, that is the response 
of the animal to challenge with the chemi-
cal, are performed after a recovery period to 
avoid carry-over from irritant response. 
Elicitation protocols have used guinea-pigs, 
rats or mice, with induction often by the 
dermal route, but occasionally by inhala-
tion. Challenges may be either single or 
multiple. After challenge, the physiological 
response may be measured (breathing rate, 
tidal volume....or a combination of several 
of them, the enhanced pause (Penh)), and 
depending on the agent, pathophysiology 
and species, early (<= 1 h) or late (~ 16-
24 h) responses or both may be observed. 
Another means to investigate pathological 
changes is the broncho-alveolar lavage 
(BAL) technique, where in the fluid gained 
(BALF) the total number and/or concentra-
tion of polymorphnuclear neutrophils 
(PMNs), eosinophilic neutrophils (Eos), 
lymphocytes (Lymph), alveolar macro-
phages (AM), protein and lactate dehydro-
genase (LDH) may be elevated. Further-
more in the LLN assay for dermal sensitisa-
tion, the lung associated lymph nodes 
(LALN) may be investigated.  
For the relevance of these different parama-
ters for the evaluation of respiratory sensiti-
sation and irritation, the reader is referred to 
the literature cited above.  
 
RESULTS 
Guinea pig 
a) Published data for guinea pig with 
dose-response regimes 
Karol et al. (1980) used TDI as positive 
control for the investigation of p-toluene-
isocyanate induced hyperreactivity in the 
guinea pig. A 3 h exposure to 0.25 ppm 
TDI for 5 consecutive days was irritating as 
demonstrated by reduced respiratory rate 
during exposure. A challenge concentration 
of 0.02 ppm for 30 min on days 11, 12, 22 
and 23 was slightly irritating, causing a 
small reduction in respiratory rate. Howev-
er, after challenge there was a slight in-
crease of respiratory rate suggesting a pos-
sible threshold for an elicitation response, 
but there were insufficient data to show a 
dose-response. 
Karol (1983) induced guinea pigs by 3 
h/d exposure against 0.12 to 10 ppm TDI 
for 5 days. On day 22, challenge with TDI-
GSA-adduct resulted in pulmonary hyper-
sensitivity and increased levels of specific 
antibodies were present in animals induced 
with 0.36 ppm or higher. Whereas 0.12 
ppm (TDI) for 3 h/5 d was regarded as min-
imally irritating, 0.02 ppm for 15 weeks 
was described as non-irritating. Exposure 
against 0.02 ppm for 6 h/d over 70 days al-
so did not result in increased antibody titre 
and pulmonary hypersensitivity. In this pa-
per it was shown, that not all animals with 
increased IgG levels also showed a physio-
logic response. 
Botham et al. (1988) exposed groups of 
10 guinea pigs against 0, 1, 3 or 4 ppm TDI 
for 3 h/d over 5 days. There was an increase 
in the group mean respiratory response to 
TDI-GSA challenge at about 23 or 30 days, 
but the changes were rather similar, indicat-
ing that the response was already maximal 
at the 1 ppm concentration.  
Six guinea pigs per dose were exposed 
against 0, 0.02, 0.2, 0.6 or 1.0 ppm TDI for 
3 h/d for 5 consecutive days (Huang et al., 
1993a). After 3 weeks, respiratory rate was 
measured after 15 min exposure against an 
aerosol containing 1 % TDI-GSA. At 
0.02 ppm induction dose respiratory rate 
was indistinguishable from control. Specific 
antibodies were also undetectable in ani-
mals exposed to 0.02 ppm TDI. At 0.2 ppm 
induction dose, 3 guinea pigs showed a 
weak increase in respiratory rate and one a 
moderate response.  
In another experiment, Huang et al. 
(1993b) exposed groups of 7 guinea pigs 
against 0, 0.03, 0.11 or 0.37 ppm TDI for 
3 h/d for 5 days. On day 21, the animals 
were challenged with 0.37 ppm TDI for 
30 min, and 30 min after end of challenge 
exposure, blood was collected and analysed 
for histamine content and mast cell degran-
ulation index (MCDI). Neither histamine 
content nor MCDI were significantly ele-
vated at 0.03 ppm induction dose. At 
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0.11 ppm, however, both parameters were 
significantly elevated.  
In a parallel experiment, the induction 
dose for all groups was 0.37 ppm, and the 
challenge doses 0, 0.03, 0.11 or 0.37 ppm. 
In this series, histamine content in blood 
and MCDI were significantly elevated at 
0.11 ppm challenge dose and above, but not 
at 0.03 ppm.  
Huang et al. (1993b) did not explicitely 
mention dose-response and thresholds; 
therefore, we applied the Benchmark Dose 
Software to the data presented by the au-
thors. As the histamine content in blood 
seemed to be most sensitive of those end-
points investigated, the corresponding data 
from Huang et al. (1993b) are given in Fig-
ure 1. When evaluated with the Benchmark 
Dose Software, the BMDL10 against elevat-
ed histamine level is 0.028 ppm, similar to 
the NOAEC of the experiment. The data are 
consistent with a steep dose-response be-
tween 0.03 and 0.11 ppm at which point the 
response is maximal. 
 
 
Figure 1: Histamine content in guinea pig blood 
(mean + SD) 30 min after challenge with 
0.37 ppm for 30 min, depending on induction 
dose 
 
Six guinea pigs per dose were induced 
by inhalation of 0, 0.02, 0.2, 0.6 or 1.0 ppm 
TDI for 3 h/d on five consecutive days 
(Aoyama et al, 1994)., The animals were 
challenged with 0.02 ppm TDI for 15 min 
21 days after the last exposure. The respira-
tory rate was checked in whole-body ple-
thysmographs during challenge and 60 min 
thereafter. After 0.02 ppm induction dose, 
none of the six exposed animals showed a 
significant increased respiratory rate against 
control, whereas at 0.2, 0.6 and 1.0 ppm 
6/6, 4/6 and 5/6 animals reacted; a positive 
reaction was a respiratory rate at or above 
control mean plus 3 standard deviations. 
From 0.2 ppm and above there was no 
dose-response in absolute respiratory rate.  
Ban et al. (1997) applied a variety of 
exposure regimes to groups of 5 guinea 
pigs. Group a received 3 ppm for 1 h. 
Group b received 1 ppm for 2 h, group c 
was exposed against 1 ppm for 2 h on two 
consecutive days, group d and e received 
0.066 or 0.11 ppm for 48 h and group f re-
ceived 1 ppm for 3 h on five consecutive 
days. LALNs were analyzed at 0, 24 h, 48 h 
or 5 d after cessation of exposure. The total 
cell number and the percentage of dendritic 
cells was significantly increased in all 
groups without group d and e.  
Amongst other dosing regimens, 
Pauluhn (1997) induced 8 guinea pigs per 
group intradermally (0.3 % TDI) on day 0, 
and via inhalation for 3 h to 0.5, 1.5, 3.5, 
6.2 or 6.9 ppm TDI on days 0-4. On day 21 
the animals were challenged with 
0.067 ppm TDI for 30 min. Respiratory rate 
and flow derived parameters were analysed 
individually pre- and post-challenge; how-
ever, a clear dose-response was not observ-
able and the lowest dose led to pulmonary 
responses in some animals.  
Pauluhn and Mohr (1998) induced 8 
guinea pigs per group intradermally on day 
0 and via inhalation against 0.5, 1.5, 3.9, 
6.3 or 7.0 ppm TDI for 3 h/d over 5 days 
(amongst other exposure regimes). In this 
design, 0.5 ppm was mildly irritating and 
was used as the challenge concentration for 
30 min on day 22. On day 28, the guinea 
pigs were challenged with 50 mg/m³ TDI-
GSA-conjugate for 15 min. The TDI-GSA 
elicited an increased respiratory response in 
more animals than neat TDI. However, a 
convincing dose-response dependent on the 
inhalation induction concentration was not 
observed. The severity of respiratory re-
sponse showed some correlation with the 
influx of eosinophils.  
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Shiotsuka et al. (2000) induced guinea 
pigs with 1.35 ppm either 2,4- or 2,6-TDI 
for 3 h/d on five consecutive days. In week 
four and five, the animals were challenged 
with 0.018 to 0.046 ppm TDI for 60 min, 
followed by a 16 h monitoring of the res-
piratory rate. In week six, the animals were 
challenged with aerosolized TDI-GSA con-
jugate, and the respiratory rate was moni-
tored. Maximum response to any challenge 
was in 50 % of the group. As there were 
exposure groups where the isomer was 
switched from induction to challenge, this 
study demonstrated the full cross-reactivity 
of 2,4- and 2,6-TDI. 
 
b) Irritation protocols with guinea pig 
When exposed to 0.029 ppm TDI for 
5 h per day for 20 days consecutively, the 
tracheal smooth muscle of guinea pigs ex-
cised 20 h after cessation of exposure was 
hyperresponsive to carbachol, but not to 
beta-adrenergic agonists (McKay and 
Brooks, 1984). 
Wong et al (1985) exposed 8 guinea 
pigs against 1.4 ppm TDI for 3 h/d on 4 
consecutive days, and 24 guinea pigs 
against 0.02 ppm for 6 h/d 4 d/w for 14 w. 
Ventilatory performance was tested before, 
during and after the exposure period by 
adding 10 % CO2 to the air. In the 1.4 ppm 
group, the CO2 challenge created an in-
crease in the pressure change in the whole 
body plethysmograph – which is propor-
tional to the tidal volume - , and histopatho-
logically in 7/8 of the GP interstitial in-
flammation as well as mild goblet cell hy-
perplasia was observable. No changes 
against control were observed in the 
0.02 ppm TDI group. 
Exposure to 2 ppm TDI for 1 h caused a 
significant increase in non-specific airway 
hyperresponsiveness to ACh injection, 
bronchial epithelial injury and influx of eo-
sinophils and PMNs in the airway mucosa 
of guinea pigs (Gordon et al., 1985). Ani-
mals exposed to 1 ppm TDI for 1 h showed 
a similar increase in PMN-influx, but no 
statistically significant increase in airway 
hyperresponsiveness, although two animals 
were much more responsive than the re-
maining six of that group. 
Miller et al. (1986) investigated the 
morphology and histology of the lower res-
piratory tract of guinea pigs after inhalation 
of 0.030 or 0.26 ppm TDI for 5 h/d, 5 d/w 
for 2 w or 3.1 ppm TDI for 4 h/d for 5 d. 
The two low exposure concentrations pro-
duced a few slight alterations but no in-
flammation, while the latter was evident 
after exposure to 3.1 ppm TDI. 
Gagnaire et al. (1988) exposed guinea 
pigs against 1.2 ppm TDI for 4 h (A), 1.078 
ppm (B) and 0.126 ppm (C) for 4 h on two 
consecutive days, 0.118 ppm for 48 h (D), 
0.045 ppm (E) and 0.023 ppm (F) for 7 d 
continuously. All groups except C reacted 
with bronchial constriction to intravenously 
administered ACh 20 h after cessation of 
exposure. These results suggest some ele-
ment of concentration * time (C * T) may 
be important, where T is the time interval of 
continuous exposure. The exposure regimen 
of 0.5 ppm * h (C * T = 0.126 ppm * 4 h) 
was without effect, and while it was not the 
lowest exposure concentration, the C * T 
product was the lowest used. For compari-
son, exposure scenario F, with the lowest 
concentration (0.023 ppm) has a C * T 
product of 3.86 ppm * h. 
Raulff et al. (1995) exposed guinea pigs 
for 2 h/d for 5 consecutive days against 0, 
0.01, 0.02 or 0.03 ppm TDI. 1 h after the 
last exposure, animals were sacrified and 
BALF was investigated. Protein, macro-
phages, lymphocytes, neutrophiles, throm-
boxane B2 and prostaglandin D2 were un-
affected; leucotrienes were increased with 
increasing dose, whereas eosinophils were 
significantly increased although inversely 
proportional to the dose. 
Groups of 20 guinea pigs received 
3 ppm TDI for one hour (Gagnaire et al., 
1996). Half of a dose group was checked 
for ACh triggered airway hyperreactivity, 
and the other half was subjected to bron-
chio-alveolar lavage at 0.5 h (a), 4 h (b), 
24 h (c), 48 h (d) and 1 w (e) after expo-
sure. Group f was exposed against 
0.08 ppm for 48 h, and group g received 
0.046 ppm for 1 w; 24 h after exposure, 
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groups f and g were analysed regarding 
non-specific hyperreactivity and BALF pa-
rameters. Bronchial hyperresponsiveness to 
ACh was evident as early as 30 min after 
exposure, remained on nearly the same lev-
el up to 48 h after exposure and declined to 
baseline values after 7 days. PMNs in 
BALF were significantly increased 4 h after 
exposure, peaked at 24 h, were still signifi-
cant at 48 h and declined to baseline levels 
7 d after exposure. Groups f and g also 
showed a clear non-specific bronchial hy-
perresponsiveness 24 h after exposure; 
PMNs in BALF, however, were not elevat-
ed. 
In a follow-up experiment, guinea pigs 
were exposed against 3 ppm TDI for 1 h or 
0.03 ppm TDI for 8 weeks (Gagnaire et al., 
1997). Bronchial hyperresponsiveness to 
ACh was increased in both groups 1 h after 
exposure. Pre-treatment with capsaicin 
eliminated the TDI-induced hyperrespon-
siveness to ACh. Tachykinins released by 
sensory nerve fibres seem to play an im-
portant role in TDI induced bronchial non-
specific hyperreactivity, although the de-
tailed mechanism remains obscure.  
Huang et al. (1997) investigated isolated 
guinea pig trachea in tissue baths contain-
ing different concentrations of MCh. When 
the lumen of the tracheas was perfused with 
air containing TDI, 0.02 or 0.07 ppm for 
30 min resulted in an increased contractibil-
ity upon MCh exposure, whereas 
0.005 ppm were without effect. On epithe-
lium-denuded trachea, 0.07 ppm TDI were 
without effect against control. Depletion of 
tachykinins by capsaicin-pretreatment did 
not prevent induction of hyperreactivity by 
exposure to 0.07 ppm TDI in the presence 
of intact epithelia.  
Guinea pigs were exposed against 0, 
0.0025, 0.005, 0.010 and 0.020 ppm TDI, 
MDI or HDI for 6 h/d, 5 d/w over 4 weeks 
(Marek et al, 1999). Directly after cessation 
of exposure, or after an 8 week recovery 
period, the trachea was prepared and its 
constriction in a physiological bath contain-
ing ACh was measured. Animals exposed 
to 0.01 and 0.02 ppm had a hyperreactive 
trachea. Animals sacrified after an 8 week 
recovery period did not have hyperreactive 
trachea. 
 
c) Summary and conclusion guinea 
pig 
In the following Tables 1a and 1b, some 
of the guinea pig studies are summarized. A 
selection was made with respect to concise, 
but sufficiently complete dose-response in-
formation. For exposure regimes more or 
less representative of workplace exposure, 
about 0.02 ppm seems to be the threshold 
for induction and elicitation of specific air-
way hyperresponsiveness as well as for 
immunological parameters such as LALN 
cells, histamine titre and mast cell degranu-
lation index. A NOEC for non-specific hy-
perresponsiveness to ACh or MCh directly 
after exposure to TDI is 0.005 ppm TDI. 
Comparing data from Huang et al (1993b), 
Aoyama et al (1994) and Shiotsuka et al 
(2000) – all having the same induction re-
gime and very similar elicitation protocols 
– indicates that high induction doses result 
in low elicitation LOAECs / NOAECs and 
vice versa. A similar relationship is de-
scribed and discussed for skin sensitisers by 
Hostynek and Maibach (2004).  
 
Mouse 
 
a) Mouse studies with dose-response 
and/or threshold information 
against respiratory sensitisation 
C57BL/6 mice exposed to 0.02 ppm 
TDI for 4 h/d, 5 d/w for 6 weeks (Matheson 
et al., 2005). After 14 days without treat-
ment, challenge against 0.02 ppm TDI for 
1 h, they showed an allergic response evi-
denced by airway inflammation, eosinophil-
ia, increased PMNs and lymphocytes and 
goblet cell metaplasia. A further 24 h after 
TDI challenge, airway hyperresponsiveness 
was evident upon MCh challenge. Induc-
tion with 0.5 ppm TDI once for 2 h did not 
trigger such responses after challenge.  
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Table 1a: Results of guinea pig studies: sensitisation 
Reference Induction Challenge and endpoint 
investigated 
NOAEC LOAEC 
Karol et al., 
1980 
0.25 ppm, 3 h/d on 
5 consecutive days 
0.02 ppm for 30 min on days 
11, 12, 22 and 23; respiratory 
rate 
- 0.25 ppm 
Karol, 1983 0.12 to 10 ppm; 3 h/d, 5 
d (a); 0.02 ppm for 6 h/d, 
5 d/w, 12 w (b) 
1 % TDI-GSA-aerosol days 
21 and 22, respiratory rate 
and antibody-titre  
0.12 ppm (a); 
0.02 ppm (b) 
0.36 ppm (a);  
Botham et 
al., 1988 
0, 1, 3 or 4 ppm, 3 h/d, 5 
d 
TDI-GSA, days 23 and 30; 
respiratory rate 
- 1 ppm 
Huang et al., 
1993a 
0, 0.02, 0.2, 0.6 or 1.0 
ppm, 3 h/d, 5 d 
Day 21, 1 % TDI-GSA aero-
sol; respiratory rate 
0.020 ppm 0.2 ppm 
Huang et al., 
1993b 
0.03, 0.11 or 0.37 ppm , 
3 h/d, 5d (a); 0.37 ppm, 
3 h/d, 5d (b) 
Day 21: 0.37 ppm, 30 min 
(a), or 0.03, 0.11 or 0.37 ppm 
(b). Histamine titre and mast 
cell degranulation index in 
whole blood  
0.03 ppm (a, b) 0.11 ppm (a, b) 
Aoyama et 
al., 1994 
0.02, 0.2, 0.6, 1.0 ppm, 
3 h/d, 5 d 
Day 21, 0.02 ppm TDI for 15 
min; respiratory rate during 
challenge and following 60 
min  
0.02 ppm 0.2 ppm 
Ban et al., 
1997 
1 ppm, 1 h or 2 h; 
1 ppm, 2 h/d, 2 d; 0.066 
or 0.11 ppm for 48 h; 1 
ppm, 3 h/d, 5 d  
Cell number and percentage 
of dendritic cells in LALN at 
different time points after 
exposure 
0.11 ppm, 48 h 1 ppm, 1 h 
Pauluhn and 
Mohr, 1998 
intradermal on day 0 
and via inhalation to 0.5, 
1.5, 3.9, 6.3 or 7.0 ppm 
TDI for 3 h/d over 5 days 
0.067 ppm TDI, day 21; res-
piratory rate before, during 
and following challenge 
- 0.5 ppm 
Shiotsuka et 
al., 2000 
1.35 ppm, 3 h/d, 5 d Weeks 4, 5 (TDI) and 6 (TDI-
GSA); respiratory rate over 
16 h 
- 0.018-
0.046 ppm TDI 
(elicitation) 
 
 
Table 1b: Selected results of guinea pig studies: irritation 
Reference Induction Challenge and endpoint 
investigated 
NOAEC LOAEC 
McKay and 
Brooks, 
1984 
0.029 ppm, 5 h/d, 20 d 
continuously 
20 h after exposure tracheal 
smooth muscle tonus against 
beta-agonists and carbachol 
0.029 ppm (be-
ta-agonists) 
0.029 ppm 
(carbachol) 
Wong et al., 
1985 
1.4 ppm, 3 h/d, 4 d (a); 
0.02 ppm, 6 h/d, 4 d/w, 
14 w (b)  
Ventilatory performance on 
CO2–challenge; histopathol-
ogy 
0.020 ppm (b) 1.4 ppm (a) 
Gordon et 
al., 1985 
1 and 2 ppm for 1 h AHR to ACh 2 h after expo-
sure, histopathology 
1 ppm (AHR, 
histopathology) 
2 ppm 
Miller et al., 
1986 
0.03, 0.26 ppm, 5 h/d, 5 
d/w, 2 w; 3.1 ppm 4 h/d, 
5 d 
Morphology and epithelial 
damage of lower respiratory 
tract 
0.26 ppm 3.1 ppm 
Raulff et al., 
1995 
0.01, 0.02 or 0.03 ppb,  
2 h/d, 5 d 
1 h after last exposure, in-
vestigation of BALF  
0.03 ppm 
(PMNs, Eos) 
0.01 ppm  
(leucotrienes) 
Gagnaire et 
al., 1997 
0.03 ppm, 8 w continu-
ously 
Response to ACh, 1 h follow-
ing exposure 
- 0.03 ppm 
Marek et al., 
1999 
0.0025, 0.005, 0.01 or 
0.02 ppm, 6 h/d, 5 d/w,  
4 w 
Contraction of excised tra-
chea in ACh bath, 1 h or 8 w 
after cessation of exposure 
0.005 ppm (1 h 
after exposure); 
0.02 ppm (8 w 
after exposure) 
0.001 ppm (1 h 
after exposure) 
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Ban et al. (2006) induced and chal-
lenged BALB/c mice by different inhala-
tion, intratracheal and/or dermal regimes. 
The mildest inhalation-only protocol, 
which was induction with 3 ppm TDI for 
4 h for days 1-3 and challenge with 
0.3 ppm for 4 h/d at days 9 and 14, caused 
a clear inflammatory response in the lung 
and goblet cell hyperplasia. This exposure 
and response is considered to be markedly 
above the LOAEC.  
Arts et al. (2008) investigated into a 
respiratory lymph node assay, a pendant to 
the murine LLN assay for dermal sensitiz-
ers. Exposures to TDI were at 7.4 mg/m³ 
for 45, 90, 180 or 360 min/d to BALB/c 
mice on three consecutive days. Three days 
after the last exposure mandibular (and au-
ricular) lymph nodes were excised and 
DNA proliferation was quantified by in-
corporation of ³H-thymidine. For TDI in-
halation the interpolated ED3-value was 
about 300 mg*min/m³, equating to 
0.63 mg/m³ or 90 ppb for an 8 h exposure. 
This concentration * time regime is irritat-
ing (see below). Histopathological altera-
tions were confined to the upper respirato-
ry tract.  
 
b) Mouse studies with dose-response 
and/or threshold information 
against respiratory irritation  
The mouse is also used as a model for 
respiratory irritation. The protocols applied 
and endpoints covered, extend into sensiti-
sation protocols and from a mechanistic 
point of view, as well as for interpretation 
of the sensitisation dose-response data, we 
thought it to be useful to include these 
studies. 
Sangha and Alarie (1979) investigated 
the respiratory irritation of mice by TDI 
exposure. Mice were exposed for 3 h per 
day for 5 consecutive days and reduction 
of respiratory rate was measured directly 
after exposure. Concentrations of 
0.023 ppm and higher resulted in a dose-
dependent decrease of the respiratory rate, 
which became more prominent after re-
peated exposure. Concentrations of 0.007 
and 0.018 ppm did not produce a reduction 
in respiratory rate, neither after the first nor 
after repeated exposures. The authors con-
cluded that at concentration of 0.023 ppm 
TDI and above, administered over 3 h, re-
sulted in damage that did not fully recover 
overnight. A 15 d exposure free period, 
however, was sufficient to set the response 
of previously exposed mice (up to 1.2 ppm 
for 5 h on three consecutive days) back to 
that of naïve mice. Increase of exposure 
time from 10 to 180 min resulted in higher 
reductions in respiratory rate. A further 
increase to 240 min did not create further 
reductions. From a plot for (% decrease in 
respiratory rate) against (log [TDI]) given 
in that paper it can be concluded, that the 
threshold for irritation is in the range of 
0.01 to 0.02 ppm TDI for an exposure time 
of at least 180 min.  
In a chronic inhalation study, 90 CD-1 
mice per gender and dose were exposed to 
0, 0.05 or 0.15 ppm TDI for 6 h/d, 5 d/w 
for up to 2 years (Owen, 1986). Over the 
whole term of the study, incidences for ne-
crotic rhinitis were 0/90, 4/90 and 22/90 
for males, and 0/90, 8/90 and 29/89 for 
females. When we analysed the data for 
rhinitis with the Benchmark Dose Software 
female mice were more susceptible than 
males against this endpoint, and for the 
different dose-response models the BMD10 
ranges from 0.044 to 0.055 ppm, the 
BMDL10 from 0.032 to 0.035 ppm. 
Zheng et al. (2004) exposed BALB/c 
mice against 0, 0.34, 0.86 or 1.38 ppm TDI 
for 4 h/d over 5 days. 20 h after the 1st , 3rd 
and 5th exposure BALF was analyzed for 
total cell count, macrophages, lympho-
cytes, neutrophils and eosinophils. Satellite 
groups were used to investigate histopatho-
logical changes as goblet cell metaplasia, 
eosinophilic infiltration and epithelial 
damage in trachea and bronchi. These his-
topathological changes were graded cate-
gorically as 0 = no change, 1 = very slight, 
2 = slight, 3 = moderate to severe and 4 = 
severe. The onset and severity of histo-
pathological changes correlated well with 
the earliest statistically significant increase 
and content of neutrophils and eosinophils 
in BALF. To generate dose-response in-
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formation, we applied the Benchmark 
Dose Software to the data of Zheng et al. 
(2004), using continuous models with 
BMR = Meancontrol + 1 STDcontrol. 
The best fit was achieved with a poly-
nom 2nd degree for neutrophils with BMD 
= 0.096 ppm and BMDL = 0.07 ppm. For 
eosinophils, we got BMD = 0.132 ppm and 
BMDL = 0.092 ppm.  
The influence of multiple challenges on 
endpoints was investigated by Vanoirbeek 
et al (2009). Interestingly, repeated chal-
lenges can dampen the early respiratory 
response after intranasal challenge and the 
non-specific hyperresponsiveness against 
MCh 22 h thereafter. This finding is im-
portant for the discussion of appropriate 
challenge protocols.  
Lindberg et al. (2011) exposed mice 
against 0.15, 0.2 or 0.32 ppm TDI for 1 h/d 
over 5 d. The lowest dose was clearly irri-
tating as detected by changes in respira-
tion. The breathing frequency did not de-
crease with repetition of exposure.  
 
c) Summary of mouse data and con-
clusion 
Some mouse data are summarized in 
Table 2. With respect to dose-response, the 
mouse-database is smaller than that for 
guinea pigs. As well as for the guinea pig, 
responses driven by irritation seem to be 
triggered at lower concentrations than re-
sponses modulated by the adaptive im-
mune system. For irritation, the threshold 
is around 0.02 ppm, and the data available 
indicated that prevention of irritation 
would perhaps prevent sensitisation by 
TDI. That would fit to the view presented 
by Matheson et al. (2002) and Johnson and 
Luster (2006), that inflammation is likely 
an early stage or a prerequisite for the de-
velopment of TDI-induced asthma.   
 
Rat 
Pauluhn (2012) induced Brown-
Norway rats dermally on day 0 and 7 with 
1 % TDI in acetone-olive oil or vehicle 
alone (control). On days 20, 35 and 50 the 
animals were exposed to 70 mg/m³ for 
30 min. This dose was chosen to achieve a 
minimal irritation of the lung. On day 65 
the animals were challenged with either 
1.5, 6, 20 or 70 mg/m³ TDI for 30 minutes. 
One day after the challenge, BALF and 
LALN and histopathology were investigat-
ed. For these protocol conditions 6 mg/m³ 
for 30 min was the NOAEC for elicitation 
in sensitized rats.  
 
 
 
Table 2: Results of selected mouse studies showing irritation and sensitisation  
Reference Induction Challenge and endpoint 
investigated 
NOAEC LOAEC 
Sangha and 
Alarie, 1979 
3 h/d for up to 5 d No challenge; respiratory rate 
during exposure 
0.018 ppm / 5 d 0.023 ppm / 5 d 
Owen, 1986 0, 0.050, 0.15 
ppm; 6 h/d, 5 d/w, 
104 w 
No challenge. Histopathology: 
necrotic rhinitis 
0.032 ppm 
(BMDL10) 
0.054 ppm 
(BMD10) 
Matheson et 
al., 2005 
0.02 ppb, 4 h/d, 
5 d/w, 6 w 
0.02 ppm TDI, 1 h; AHR, infiltra-
tion of PMNs and Eos etc in lung 
and nares 
- 0.02 ppm 
Zheng et al., 
2004 
4 h/d, 5 d  No challenge; BALF and histolo-
gy 24 h after exposure 
0.07 ppm 
(BMDLmean+1SD) 
0.096 ppm 
(BMDmean+1SD) 
Arts et al., 
2008 
1 ppm for 45, 90, 
180 or 360 min/d, 
3 d 
ED31) mandibular lymph nodes 
3 d after exposure; rhinitis 
0.09 ppm (ED3) 
for 8 h/d 
1 ppm / 45 min 
(rhinitis) 
Johnson et 
al., 2007 
0.05 ppm, 4 h/d, 
12 d 
None or 0.05 ppm, 4 h/d, 3 d; 
breathing patterns, histology 
- 0.05 ppm 
Lindberg et 
al., 2011 
0.15, 0.2, 
0.32 ppm 1h/d for 
5 d 
None. Respiratory changes  0.15 ppm 
1) lymph node stimulation 3-fold above control 
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Besides this single study, for the rat we 
did not find TDI inhalation sensitisation 
studies. The studies cited here are all irrita-
tion protocols with repeated dose regimes. 
Only a two-generation study, where rhini-
tis was observed and evaluated, delivers 
some sensitisation dose-response infor-
mation.  
A 104 week cancer study where rats 
were exposed to 0.05 and 0.15 ppm TDI 
for 6 h/d, 5 d/w for 104 w, reported nasal 
irritation at the lowest dose (Owen, 1984). 
As for the mouse, females were more sus-
ceptible to TDI-induced rhinitis than 
males. We analysed the data with the 
Benchmark Dose Software and the BMD10 
ranged from 0.016 to 0.028 ppm and the 
BMDL10 stretched over a range of 0.007 to 
0.023 ppm. The logProbit model delivered 
a BMDL10 of 0.002 ppm, which was much 
lower than the corresponding BMD10 of 
0.019 ppm and, therefore, has to be regard-
ed with caution. 
Male SD-rats were exposed to 0, 0.082, 
0.184, 0.305, 0.664 or 1.087 ppm TDI for 
4 h (Hesbert et al., 1991). BALF was col-
lected 20 h after the end of exposure, and 
analyzed for neutrophils and macrophages 
as markers for inflammation. The number 
of neutrophils was increased in a dose-
dependent manner, with the lowest dose 
being undistinguishable from the control, 
0.184 ppm showing elevated, although sta-
tistically non-significant levels and from 
0.305 ppm onwards statistically very sig-
nificant increases. The number of macro-
phages in the BALF showed neither a 
dose-response nor was it significantly al-
tered against the control. When the 
Benchmark Dose Software is applied to the 
data, setting the benchmark risk at the 
mean + one standard deviation of the con-
trol, acceptable data fits can be generated 
with the Hill Model only (BMD = 
0.2 ppm; BMDL = 0.16 ppm).  
Bonnet et al. (1994) exposed SD-rats 
for 4 h or 7 d continuously to TDI. At the 
end of exposure, tracheae were excised and 
the mucociliary beat frequency and number 
of active regions investigated. The 7 d con-
tinuous exposure was more critical than the 
4 h exposure. In terms of reduced count of 
active regions and in terms of beating fre-
quency, 0.020 ppm was the NOAEC for 
7 d continuous exposure, whereas 
0.05 ppm was the LOAEC. After a 7 d re-
covery time, trachea of animals exposed to 
0.05 ppm for 7 d showed normal activity, 
whereas animals exposed to 0.1 ppm still 
showed decreased activity. 
In a two-generation study CD rats were 
exposed to 0, 0.02, 0.08 or 0.3 ppm TDI 
for 6 h/d and 5 d/w (Tyl et al., 1999). Ten 
animals per dose were subjected to histo-
pathological investigation of the respirato-
ry tract. The lowest dose, 0.02 ppm, still 
caused minimal to mild rhinitis in 3 F0 
males and females, respectively. In the F1 
generation, 7 of 10 males and 4 of 10 fe-
males had minimal to moderate rhinitis. 
The histopathological alterations were con-
fined to the upper respiratory tract. We an-
alysed the rhinitis as dichotomos data with 
the Benchmark Dose Software for the F0 
generation. Data from males and females 
were combined, and we made no grading 
in terms of severity of the rhinitis. At con-
centrations of 0, 0.02, 0.08 and 0.3 ppm, 
1/20, 6/20 14/20 and 18/20 animals devel-
oped rhinitis. Those models providing an 
acceptable fit to the data delivered values 
for the BMD10 around 0.007–0.01 ppb and 
for the BMDL10 of 0.003 to 0.007 ppm. 
The logProbit model delivered a BMDL10 
of 0.001 ppm, which is much lower than 
the BMD10 of that model, 0.007 ppm and 
therefore, should be regarded with caution. 
Benchmark dose analysis was also per-
formed for the F1 generation, but fits of 
curves were generally very poor. Only the 
logLogistic model delivered a P-value 
above 0.1 (0.1424) with a BMD of 
0.0008 ppm and a BMDL of 2 x 10-8 ppm. 
As was observed with mice (Lim et al., 
2007), it might be that sensitised dams pass 
on a factor to offspring which increased 
susceptibility, affecting results. 
In the F1 generation, rhinitis was more 
prevalent and the severity at the lowest 
dose was slightly increased.  
SD-rats received inhalation exposures 
to doses of 0.01, 0.1 or 1.0 ppm TDI for 
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8 h (Pons et al., 2000). 18–24 h after expo-
sure, rats were sacrified. At the highest 
concentration tested, there were no histo-
logical lesions observable in the lung (loss 
of cilia, epithelial shedding). At 1.0 ppm, 
expression of CYP 2B1, but not 3A1 was 
depressed. Neither CYP 1A1 and 2E1 nor 
different GST iso-enzymes were induced.  
Groups of 10 Wistar rats per dose were 
exposed to 0, 0.38 or 1.2 ppm TDI for 
4 h/d over 5 d (Kouadio et al., 2005). Clin-
ically hyperrhinorrhea and sneezing were 
observed at 0.38 ppm, and more pro-
nounced at 1.2 ppm. 24 h after the last ex-
posure BALF was collected and analysed. 
Eosinophils, neutrophils, macrophages and 
lymphocytes were increased in a dose-
dependent manner, the latter statistically 
significant only at 1.2 ppm, the others 
achieving statistical significance also at the 
low concentration. Histopathologically, a 
dose-dependent eosinophilic infiltration in 
the bronchi and goblet cell metaplasia was 
observed. Unfortunately, no lung function 
parameters were investigated. The authors 
referred to a publication of Zheng et al. 
(2001), where laboured breathing of TDI 
sensitized Wistar rats could be observed in 
parallel to bronchial eosinophilia, neutro-
philia and goblet cell metaplasia. This lat-
ter study had no dose-response protocol 
and the authors used intranasal instillation.  
An acceptable fit of the functions pro-
vided by the Benchmark Dose Software 
was not possible without modifications. To 
avoid over-parameterization of the poly-
nomal model of 2nd degree (y = β0 + β1*x + 
β2*x²), β0 was fixed to the mean of the 
control group. Doing this, and taking the 
mean + 1 standard deviation of the control 
as benchmark risk, concerning PMNs in 
BALF the BMDL is 0.067 ppm, whereas it 
is 0.097 ppm against Eos. 
Table 3 summarises the rat data. A typ-
ical respiratory induction and challenge 
protocol with rats was not identified. The 
lowest endpoints obtained are 0.007-
0.023 ppm as BMDL10 for rhinitis after 
chronic exposure, 0.067 ppm as BMDL for 
neutrophils in BALF and 0.020 ppm as 
NOAEC for mucociliary beat. For the lat-
ter, the exposure regime was more strin-
gent, which might explain the lower value. 
As an alternative explanation, the mucocil-
iary beat might be affected at lower con-
centrations than those resulting in signs of 
inflammatory changes in the lung.  
 
 
 
 
Table 3: Results of selected rat studies showing irritation and sensitisation 
Reference Induction Challenge and endpoint 
investigated 
NOAEC LOAEC 
Pauluhn, 
2012 
Topical on day 0 
and 7; 70 mg/m³, 
30 min on day 20, 
35, 50 
1.5, 6.0, 20 or 70 mg/m³ for 
30 min. BALF, LALN, respiratory 
pattern  
6 mg/m³ 20 mg/m³ 
Owen, 1984 0, 0.05 or 0.15 
ppb, 6 h/d, 5 d/w, 
104 w 
Histopathology (rhinitis) 0.007-0.023 
ppm (BMDL10) 
0.016-0.028 ppm 
(BMD10) 
Hesbert et 
al., 1991 
single 4 h expo-
sure 
no challenge; neutrophils in BALF 
20 h after exposure 
0.16 ppm 
(BMDLmean+1SD) 
0.2 ppm  
(BMDmean+1SD) 
Bonnet et 
al., 1994 
7 d continuously no challenge; mucociliary beat ex 
vivo after exposure 
0.02 ppm 0.05 ppm 
Tyl et al, 
1999 
2-gen study; 6 
h/d, 5 d/w 
No challenge; histopathology 0.01 ppm 
(BMD10); 0.07 
ppm (BMDL10) 
0.02 ppm (mini-
mal to mild rhini-
tis) 
Pons et al., 
2000 
single 8 h expo-
sure 
no challenge; sacrifice 18-24 h 
after exposure; induction / de-
pression of metabolic enzymes 
0.1 ppm 1.0 ppm 
Kouadio et 
al., 2005 
4 h/d, 5 d no challenge; histology, BALF 
PMN, Eos etc 20 h after exposure 
0.067 ppm 
(BMDLmean+1SD) 
0.087 ppm (BMD) 
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For another aromatic diisocyanate, di-
phenylmethane-4,4’-diisocyanate (MDI), it 
was shown in the Brown-Norway rat that 
the percentage of neutrophils in BALF is 
linearly associated with the AUC of the en-
hanced Pause (Penh) after challenge; the 
Penh is a measure for ventilatory function 
of airways (Pauluhn, 2008). In that publica-
tion it was demonstrated how the content of 
neutrophils in BALF from a dose-response 
study can be used to derive a threshold for 
the elicitation of an allergic response in 
sensitized Brown-Norway rats. Further, to 
induce a sensitisation in this species repeat-
ed exposure of at least minimal irritating 
concentrations of MDI is required.  
From the rat data available so far, a 
threshold for irritation / inflammation is in-
dicated and is expected to be around 0.010 
ppm. Whether this is also a threshold for 
sensitisation induction and / or elicitation is 
debatable.  
 
Rabbit 
Anaesthesised rabbits were exposed 
against 0, 0.005, 0.01 and 0.03 ppm TDI for 
4 h. Once every hour, after a 55 min expo-
sure period, the bronchial response against 
aerosolized ACh solution was checked for a 
five minute period. At 0.01 ppm and more 
severely at 0.03 ppm, an increase in airway 
resistance and bronchoconstriction was de-
tectable. 0.005 ppm TDI were without ef-
fect. Also, authors report from their experi-
ence with workers investigated for isocya-
nate induced respiratory disease, non-
specific bronchial hyperreactivity is a pre-
cursor of obstructive airway disease (Marek 
et al, 1995).  
 
Human experience 
This paper is a review of the available 
animal data where there is dose-response 
information. While experience with humans 
is extensive, except for specific challenge 
tests exposure-response data are usually not 
precise or well-controlled. Personal expo-
sure measurements are somewhat inconven-
ient, as the workers have to carry adsorp-
tion filters, partly together with impingers, 
connected to a pump. The TDI collected 
reacts wit ha derivatising agent on the filter 
/ in the impinger solution. The sampling 
device has to be brought to the analytical 
lab, and after work-up the TDI-derivative is 
quantified by high performance liquid 
chromatography coupled with an ultravio-
lett, fluorescence, electrochemical or mass-
sensitive detector (UK HSE, 1999). Person-
al paper-tape monitors have the advantage 
of direct reading, but the method of detec-
tion and quantification has limitations 
(Dharmarajan, 1996). Therefore, assessing 
thresholds in humans can not readily be un-
dertaken.  
Also, occupational experience has 
demonstrated that long term exposures 
above 0.020 ppm may result in a significant 
decline in forced expiratory volume per one 
second (FEV1) and peak expiratory flow 
rate (PEFR) over time (Ott, 2002). Also, 
incidences of OA and decline in FEV1 ap-
pear not to result at concentrations of 0.005 
ppm and below and between 0.02 and 0.005 
ppm TDI reports concerning respiratory 
effects are inconclusive ( DFG, 2003; Ott et 
al., 2003).  
Symptoms reported in combination with 
TDI overexposure are airway dysfunction, 
ranging from irritation over non-specific 
hyperresponsiveness to fully developed 
asthma symptoms (Diller, 1985, 1998; 
DFG, 2003). Breathlessness, chest tight-
ness, wheezing and coughing in conjunc-
tion with exposure at the workplace are typ-
ical symptoms reported by affected workers 
(Murdoch and Lloyd, 2010). 
Responses in sensitised subjects have 
been reported at low concentrations (1 ppb), 
although the overall exposure dose (C * T) 
appears to have an impact (Lemiere et al., 
2002). However some sensitised subjects 
did not respond at 1 ppb or at 15 ppb illus-
trating the complexity of the mechanisms 
involved.  
Volunteers exposed for 30 min to TDI 
did detect neither odour nor irritation at 
concentrations of 0.01 and 0.02 ppm. At 
0.05 ppm odour was detectable as well as 
slight irritation of the eyes and at 
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0.075 ppm irritation of the eyes was more 
apparent and there was some irritation of 
the nose (Henschler et al., 1962). 
When 10 healthy volunteers and 15 
asthmatics - who were never exposed to 
TDI before - were exposed to 0.01 ppm 
TDI for 60 min, only 1 of the 15 asthmatics 
had an asthma-like response, detected as 
100 % increase in airway resistance by 
whole-body plethysmograhy (Baur et al., 
1994). Of those asthmatics remaining, 13 
consented to be exposed to 0.02 ppm which 
triggered an asthmatic response in one indi-
vidual. 
Workers with potential exposure against 
TDI and having health complaints at the 
workplace such as chest tightness, cough 
and/or dyspnea were exposed in a whole-
body plethysmograph to 0.005 ppm TDI for 
15 min, 0.010 ppm for 30 min and then fi-
nally 0.02 ppm for 5 min (unless they 
showed an asthmatic response before the 
end of the exposures) (Baur et al., 1994). Of 
the 40 workers reporting symptoms, one 
reacted positively when exposed to 0.005 
ppm, a further 3 individuals reacted when 
exposed to 0.01 ppm and another 8 individ-
uals when exposed to 0.02 ppm. Notably, 
28 individuals did not react to the specific 
TDI challenge. This shows self-reported 
symptoms should be treated with caution 
for asthma diagnosis. 
 
DISCUSSION 
Borm et al. (1990) reviewed the availa-
ble literature at that time with respect to an 
occupational exposure limit for TDI. As 
limit for irritation, 0.006 to 0.007 ppm was 
derived. About 0.02–0.04 ppm was the limit 
for non-specific bronchial hyperresponsive-
ness (i.e., AHR), 0.012 ppm for specific 
hyperresponsiveness and 0.02 ppm for gen-
eral pulmonary function. The authors high-
lighted uncertainties of extrapolation to 
humans and the fact that the animal models 
applied did not allow evaluation of lung 
decrement. 
For better oversight the different animal 
studies were grouped according to the end-
points investigated, either of sensitisation or 
irritation. 
There are nine studies identified with 
information relating to no-effect levels and 
thresholds for induction or elicitation of 
respiratory sensitisation by TDI (Table 4a). 
While it is acknowledged that NOAEC and 
LOAEC will be dependent on the concen-
trations selected for the protocol and proto-
cols and endpoints assessed vary widely, a 
general overview may be taken. Specifical-
ly, in the guinea-pig, four studies give a 
NOAEC of 0.02 or 0.03 ppm, and in these 
studies the LOAEC ranged from 0.11 to 
0.36 ppm. Slightly higher NOAECs were 
seen where induction protocols were used 
(e.g. local lymph node studies), as opposed 
to elicitation protocols (Ban et al., 1997; 
Arts et al., 2008). For those induction pro-
tocols, the LOAEC were correspondingly 
high at 1.0 ppm. Of specific note are two 
studies which did not identify a NOAEC 
but found a LOAEC of 0.02 ppm (Karol et 
al., 1980; Matheson et al., 2005). In the 
study by Karol et al. in guinea-pigs, while 
the exposure elicited signs of irritation, 
there was weak evidence of a respiratory 
response after exposure. In mice however 
the response elicited at 0.02 ppm TDI was 
clear (Matheson et al., 2005) and it would 
seem that the induction protocol in this 
case, being 6 weeks of exposures, may be a 
factor. In summary with most elicitation 
regimens a NOAEC for respiratory sensiti-
sation is around 0.02 ppm although this 
may be higher when induction protocols are 
used. LOAECs are around 0.1 – 0.4 ppm, 
but an extended induction protocol may re-
sult in a lower LOAEC and presumably 
NOAEC.  
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Table 4a: Indices of respiratory sensitisation 
with TDI 
Reference NOAEC LOAEC 
Karol et al., 
1980 
- 0.02 ppm  
Karol, 1983  0.02 ppm 0.36 ppm  
Huang et al., 
1993a 
0.02 ppm 0.2 ppm 
Huang et al., 
1993b 
0.03 ppm  0.11 ppm 
Aoyama et 
al., 1994 
0.02 ppm 0.2 ppm 
Ban et al., 
1997 
0.11 ppm 1 ppm, 1 h 
Shiotsuka et 
al., 2000 
- 0.018-0.046 ppm 
 
Matheson et 
al., 2005 
- 0.02 ppm 
Arts et al., 
2008 
0.09 ppm, 8 
h (ED3),  
1 ppm / 45 min 
(rhinitis) 
 
Table 4b: Indices of respiratory irritation with 
TDI 
Reference NOAEC LOAEC 
McKay and 
Brooks, 
1984 
0.029 ppm 
(beta-agonists) 
0.029 ppm  
(carbachol) 
Wong et al., 
1985 
0.02 ppm 1.4 ppm  
Gordon et 
al., 1985 
1 ppm (ACh-
challenge, 
eosinophils, 
histopathology) 
2 ppm 
Miller et al., 
1986 
0.26 ppm 3.1 ppm 
Gagnaire et 
al., 1988 
0.13 ppm, 
4 h/d, 2 d. 
0.023 ppm, 7 d 
continuously 
Raulff et al., 
1995 
0.03 ppm 
(PMNs, Eos) 
0.01 ppm  
(leucotrienes) 
Gagnaire et 
al., 1996 
0.046 and 0.08 
ppm (PMN in 
BALF) 
0.046 and 0.08 
ppm (bronchial 
hyperreactivity) 
Gagnaire et 
al., 1997 
- 0.03 ppm 
Huang et al., 
1997 
0.005 ppm 0.02 ppm 
Marek et al., 
1999 
0.005 ppm (1 h 
after expo-
sure); 
0.02 ppm (8 w 
after exposure) 
0.01 ppm  
(1 h after  
exposure) 
Sangha and 
Alarie, 1979 
0.018 ppm 0.023 ppm 
Owen, 1986 0.032 ppm 
(BMDL10) 
0.054 ppm 
(BMD10) 
Zheng et al., 
2004 
0.07 ppm 
(BMDLmean+1SD) 
0.096 ppm 
(BMDmean+1SD) 
Johnson et 
al., 2007 
- 0.05 ppm 
On the other hand, an increase in expo-
sure time and exposure frequency would 
not necessarily result in lower NOAECs/ 
LOAECs, as respiratory sensitizers may 
induce tolerance (Vanoirbeek et al., 2009). 
There are several studies with various indi-
cations of respiratory irritation available 
(Tables 1b, 2). For the purposes of compar-
ison with those of respiratory sensitisation, 
for which data are available in the guinea 
pig and mouse only, the respiratory irrita-
tion NOAEC and LOAEC for these species 
are shown in Table 4b. Respiratory irrita-
tion NOAECs range from 0.005 to 
0.26 ppm, although there is a non-specific 
hyperresponsiveness outlier of 1.0 ppm, 
although there are indications of PMN in-
flux and some sensitive individuals at this 
concentration.  
The LOAECs from these studies range 
from 0.01 through 3.1 ppm. Clearly, these 
values are derived from a variety of differ-
ent protocol endpoints, and exposure con-
centrations were not necessarily set to in-
vestigate no- or low-effect levels. Neverthe-
less, it is clear that the NOAECs and  
LOAECs for respiratory sensitisation in 
guinea pig and mouse models are broadly 
similar to the NOAECs and LOAECs/ 
BMDLs for respiratory irritation in these 
species.  
Experience with guinea pigs, mice and 
rats indicate that the irritation threshold co-
incides with the NOAEC / BMDL for air-
way hyperreactivity. Across species, the 
involvement of acute inflammatory re-
sponse pathways in the development of 
airway hyperreactivity was shown. 
For another aromatic diisocyanate, di-
phenylmethane-4,4’-diisocyanate, repeated 
exposure against at least minimal irritating 
concentrations was required to sensitize 
BrownNorway rats (Pauluhn, 2008; 
Pauluhn and Poole, 2011). 
This strengthens the perception that 
both thresholds, that for irritation and that 
for respiratory hyperreactivity, are in the 
same order of magnitude. 
In general, summarizing over the differ-
ent end-points investigated, and bearing in 
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mind the specific exposure regimes, 
LOAECs and NOAECs are in the same or-
der of magnitude across species. Although 
some questions remain unresolved for the 
time being and certainly deserve more re-
search, the current animal database is not in 
contradiction of the current workplace ex-
posure limits for TDI. The animal data and 
human experience relating to the NEC for 
respiratory sensitisation are in concordance. 
Consequently, it may be considered that for 
derivation of occupational workplace expo-
sure limits application of additional factors 
is not required. For workplace safety, em-
ployees should be protected against irrita-
tion, and non-specific as well as specific 
hyperresponsiveness. The non-specific hy-
perresponsiveness is detectable after single 
exposures, indicating this is a non-immuno-
logical response. Thresholds for irritation 
and non-specific hyperresponsiveness are 
lower than those for specific airway reac-
tions. Therefore, as discussed by Pauluhn 
(2011) thresholds identified against the irri-
tation hyperresponsiveness should be pro-
tective for TDI-induced respiratory disease 
including respiratory sensitisation.  
 
CONCLUSION 
It is not the aim of this paper to judge 
the relevance of the different endpoints 
against each other. The existing data for 
TDI in animal models of respiratory sensiti-
sation and irritation demonstrate no-effect-
levels. These NEL are at similar concentra-
tions across different species. This justifies 
the use of thresholds for respiratory sensiti-
sation in human risk assessment.   
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